Abstract
A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 540-542 |
| Number of pages | 3 |
| Journal | Community Oncology |
| Volume | 7 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2010 |
ASJC Scopus subject areas
- Hematology
- Oncology
Fingerprint Dive into the research topics of 'Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer'. Together they form a unique fingerprint.
Cite this
Jana, B. R. P. (2010). Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer. Community Oncology, 7(12), 540-542. https://doi.org/10.1016/s1548-5315(11)70531-9